SG11201901477PA - Compound for use in the treatment of neurogenic orthostatic hypotension - Google Patents

Compound for use in the treatment of neurogenic orthostatic hypotension

Info

Publication number
SG11201901477PA
SG11201901477PA SG11201901477PA SG11201901477PA SG11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA
Authority
SG
Singapore
Prior art keywords
international
california
pct
treatment
orthostatic hypotension
Prior art date
Application number
SG11201901477PA
Other languages
English (en)
Inventor
Sharathchandra S Hegde
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of SG11201901477PA publication Critical patent/SG11201901477PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201901477PA 2016-08-30 2017-08-24 Compound for use in the treatment of neurogenic orthostatic hypotension SG11201901477PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381114P 2016-08-30 2016-08-30
PCT/US2017/048324 WO2018044667A1 (en) 2016-08-30 2017-08-24 Compound for use in the treatment of neurogenic orthostatic hypotension

Publications (1)

Publication Number Publication Date
SG11201901477PA true SG11201901477PA (en) 2019-03-28

Family

ID=59772789

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901477PA SG11201901477PA (en) 2016-08-30 2017-08-24 Compound for use in the treatment of neurogenic orthostatic hypotension

Country Status (20)

Country Link
US (1) US10238642B2 (es)
EP (1) EP3506900A1 (es)
JP (4) JP6853345B2 (es)
KR (1) KR102054208B1 (es)
CN (3) CN115813923A (es)
AU (1) AU2017321016B2 (es)
BR (1) BR112019003201A2 (es)
CA (1) CA3032168C (es)
CL (1) CL2019000377A1 (es)
CO (1) CO2019001137A2 (es)
IL (1) IL288194B2 (es)
MX (1) MX370970B (es)
MY (1) MY194181A (es)
NZ (1) NZ750392A (es)
PH (1) PH12019500252A1 (es)
RU (1) RU2723095C1 (es)
SG (1) SG11201901477PA (es)
TW (1) TWI731153B (es)
WO (1) WO2018044667A1 (es)
ZA (1) ZA201900640B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2358674E (pt) 2008-11-14 2013-03-05 Theravance Inc Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
US10640467B2 (en) 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
US20220168301A1 (en) * 2019-03-19 2022-06-02 Cerecor Inc Methods for treating symptomatic orthostatic hypotension
CA3180948A1 (en) * 2020-06-02 2021-12-09 Mohamed Hussein Hamdan Sublingual formulation for hypotension and syncope
TW202345817A (zh) * 2022-03-28 2023-12-01 美商施萬生物製藥研發 Ip有限責任公司 治療患有多系統萎縮之個體的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104815A (en) 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
ES2395868T3 (es) 2007-03-12 2013-02-15 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la hipotensión mediada neuralmente
PT2358674E (pt) 2008-11-14 2013-03-05 Theravance Inc Processo de preparação de compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
CN104220059A (zh) 2012-01-31 2014-12-17 灵北Na有限公司 通过给予屈昔多巴来改善姿势稳定性
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
MX2016000219A (es) * 2013-07-08 2016-05-31 Auspex Pharmaceuticals Inc Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.

Also Published As

Publication number Publication date
MX370970B (es) 2020-01-10
CL2019000377A1 (es) 2019-05-31
BR112019003201A2 (pt) 2019-10-01
JP2020023552A (ja) 2020-02-13
CN109640989A (zh) 2019-04-16
MY194181A (en) 2022-11-17
IL288194B1 (en) 2023-11-01
TWI731153B (zh) 2021-06-21
AU2017321016B2 (en) 2020-04-23
JP2019528303A (ja) 2019-10-10
US20180055831A1 (en) 2018-03-01
WO2018044667A1 (en) 2018-03-08
IL288194A (en) 2022-01-01
CA3032168C (en) 2020-04-21
CN115813923A (zh) 2023-03-21
CO2019001137A2 (es) 2019-02-19
MX2019001915A (es) 2019-07-15
JP6853345B2 (ja) 2021-03-31
JP2023159438A (ja) 2023-10-31
JP2021167344A (ja) 2021-10-21
US10238642B2 (en) 2019-03-26
ZA201900640B (en) 2019-10-30
NZ750392A (en) 2020-08-28
EP3506900A1 (en) 2019-07-10
PH12019500252A1 (en) 2019-06-03
IL288194B2 (en) 2024-03-01
KR20190040341A (ko) 2019-04-17
RU2723095C1 (ru) 2020-06-08
CA3032168A1 (en) 2018-03-08
AU2017321016A1 (en) 2019-02-21
CN115770244A (zh) 2023-03-10
KR102054208B1 (ko) 2019-12-10
TW201811329A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
SG11201901477PA (en) Compound for use in the treatment of neurogenic orthostatic hypotension
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201907034PA (en) Methods of treating influenza
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201907023UA (en) Method of reducing neutropenia
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof